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Background: The etiology and natural history of Parkinson’s disease (PD) are not well understood. 
Some non-motor symptoms such as hyposmia, rapid eye movement sleep behavior disorder, and con-
stipation may develop during the prodromal stage of PD and precede PD diagnosis by years.
oBjectives: We examined the promise and pitfalls of research on premotor symptoms of PD and 
developed priorities and strategies to understand their clinical and etiological implications.
Methods: This review was based on a workshop, Parkinson’s Disease Premotor Symptom 
Symposium, held 7–8 June 2012 at the National Institute of Environmental Health Sciences in 
Research Triangle Park, North Carolina.
discussion: Research on premotor symptoms of PD may offer an excellent opportunity to charac-
terize high-risk populations and to better understand PD etiology. Such research may lead to evalua-
tion of novel etiological hypotheses such as the possibility that environmental toxicants or viruses 
may initiate PD pathogenesis in the gastrointestinal tract or olfactory bulb. At present, our under-
standing of premotor symptoms of PD is in its infancy and faces many obstacles. These symptoms 
are often not specific to PD and have low positive predictive value for early PD diagnosis. Further, 
the pathological bases and biological mechanisms of these premotor symptoms and their relevance to 
PD pathogenesis are poorly understood.
conclusion: This is an emerging research area with important data gaps to be filled. Future 
research is needed to understand the prevalence of multiple premotor symptoms and their etiologi-
cal relevance to PD. Animal experiments and mechanistic studies will further understanding of the 
biology of these premotor symptoms and test novel etiological hypothesis.
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Introduction
Parkinson’s disease (PD) is the second most 
prevalent neurodegenerative disease and 
severely affects quality of life. More than 
1 million older U.S. adults live with PD, and 
the number will double by the year 2030 
(Bach et al. 2011). Clinical diagnosis of PD 
is currently based on the presence of motor 
dysfunction including rest tremor, bradyki-
nesia, and rigidity. PD patients also suffer 
from a wide range of non-motor symptoms—
including hyposmia (poor sense of smell), 
gastro  intestinal dysfunction, psychiatric fea-
tures (e.g., depression, anxiety, psychosis), 
sleep disorders, and mild-to-severe cognitive 
impairment—many of which are disabling 
and can be difficult to treat (Coelho and 
Ferreira 2012; Fernandez 2012) and greatly 
jeopardize the quality of life of PD patients 
(Storch et al. 2013). Pathologically, PD 
has been characterized by the loss of dopa-
mine neurons in the substantia nigra pars 
compacta, which underlies motor dysfunc-
tion, and by the presence of Lewy bodies in 
selected regions of the brain.
The cardinal motor signs of PD become 
clinically evident when approximately 50% 
of the dopaminergic neurons in the substan-
tia nigra are lost (Fearnley and Lees 1991). 
Despite symptomatic therapies for dopamine 
deficiency–related motor features, the dis-
ease continues to progress and often leads to 
severe mental and physical disabilities (Coelho 
and Ferreira 2012; Shulman et al. 2008) and 
increased mortality (Chen et al. 2006; Willis 
et al. 2012). To date, none of the available 
treatments can halt or reverse the   pathological 
and clinical progression of PD, and novel 
strategies are needed. Research on disease-
modifying strategies would be greatly assisted 
by the identification of high-risk populations.
Recent interest has focused on the non-
motor symptoms of PD, some of which may 
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predate motor signs and clinical diagno-
sis by years (“premotor symptoms” of PD). 
Accumulating epidemio  logical and clinical 
evidence suggests that hyposmia (Ross et al. 
2008), constipation (Abbott et al. 2007; Gao X 
et al. 2011; Savica et al. 2009), depression 
(Bower et al. 2010; Fang et al. 2010; Ishihara-
Paul et al. 2008; Shiba et al. 2000), anxiety 
(Bower et al. 2010; Ishihara-Paul et al. 2008; 
Shiba et al. 2000; Weisskopf et al. 2003), rapid 
eye movement sleep behavior disorder (RBD) 
(Claassen et al. 2010; Iranzo et al. 2006; 
Postuma et al. 2009; Schenck et al. 1996), 
excessive daytime sleepiness (EDS) (Abbott 
et al. 2005; Gao J et al. 2011), and autonomic 
dysfunction (Goldstein 2010) may occur well 
before the appearance of the classic motor 
dysfunction of PD. Evidence comes primar-
ily from large prospective population-based 
cohort studies that were initially established 
for research on cancer and cardiovascular dis-
ease, such as the Honolulu Asia Aging Study 
(HAAS) (Ross et al. 2008) and the Health 
Professionals Follow-up Study (Gao X et al. 
2011), and from retrospective examinations 
of archived medical records of PD cases and 
controls such as the Rochester Epidemiology 
Project (Savica et al. 2009). These findings are 
summarized in Table 1. A recent meta-analysis 
also confirmed that constipation and mood 
disorders were associated with higher risk of 
PD (Noyce et al. 2012). Hyposmia, RBD, and 
EDS were not included in this meta-analysis 
because risk estimates either were not available 
or were available from only one study.
The hypothesis that premotor symptoms 
precede the motor signs of PD is broadly 
compatible with neuropathological findings 
reported by Braak et al. (2003). This work, 
although controversial (Burke et al. 2008), 
suggests that deposition of α-synuclein in 
the form of Lewy bodies and Lewy neurites 
Table 1. Prospective evidence on selected premotor symptoms in large population-based studies.
Symptom Study/reference
Age [years 
(mean ± SD 
and/or range)]
Years of 
follow-up
No. of 
cases Assessment
Primary results 
[RR/HR/OR (95% CI)]
Timeline 
[years prior to PD]a
Hyposmia HAAS, men only 
(Ross et al. 2008)
79.7 ± 4.1 
(71–95)
≤ 8 years 35 BSIT score < 6 Lowest vs. top two quartiles: 
5.2 (1.5–25.6) for the first 
4 years, 0.3 (0.0–2.7) for the 
second 4 years of follow-up
Within 4 years
Constipationb HAAS, men only 
(Abbott et al. 2007)
60 (51–75) ≤ 24 years 96 Self-reported bowel 
movement frequency
< 1/day vs. > 2/day: 4.5 
(1.2–16.9)
Could be ≥ 12 years
REP (Savica et al. 2009) –– –– 196 Medical record review: 
constipation diagnosis 
or laxative use
2.5 (1.5–4.1) Could be ≥ 20 years
HPFS, men only 
(Gao X et al. 2011)
~ 54–89 ≤ 6 years only 156 Self-reported bowel 
movement frequency
≤ 2/week vs. daily: 
5.0 (2.6–9.6)
6 years and probably 
more
NHS, women only 
(Gao X et al. 2011)
~ 36–61 ≤ 24 years 402 Self-reported bowel 
movement frequency
Within 6 years of follow up: 
2.2 (0.8–6.1); no association 
beyond 6 years
May limit to 6 years of 
follow-up
Daytime 
sleepinessc
HAAS men only 
(Abbott et al. 2005)
77 (71–93) ≤ 8 years 43 Self-report: single 
question
2.8 (1.1–6.4) 0.5–4.9 years
NIH-AARP DH 
(Gao J et al. 2011)
52–71 4–10 years 770 Self-reported hours of 
daytime napping
≥ 1 vs. 0 hr: 1.5 (1.2–1.9) 4–10 years
RBDd Mayo Clinic (Claassen 
et al. 2010)
21–60 Only if ≥ 15 years 9 PD of 
27 RBD
Clinical diagnosis — 15–50 years
Barcelona, Spain 
(Iranzo et al. 2006)
74.1(61–86) > 2 years 7 PD of 
44 RBD
Clinical diagnosis — Could be 6–18 years
Minnesota, men only 
(Schenck et al. 1996)
54.5 — 11 PD of 
29 RBD
Clinical diagnosis — Could be by 10–29 years
Montreal (Postuma 
et al. 2009)
65.4 ± 9.3 — 19 PD of 
93 RBD
Clinical diagnosis — On average preceded by 
11 years
Depression EPIC-Norfolk (Ishihara-
Paul et al. 2008)
41–80 Median, 8 years 175 Structured 
questionnaire
Lifetime major depression 
2.1 (1.4–2.9)
Similar results for first 
episode of depression 
before or after 40 years 
of age
REP (Bower et al. 2010) 48.3 (20–69) Mean, 29 years 
(up to 45 years)
156 MMPI Quartile 4 vs. quartiles 1–3: 
1.16 (0.81–1.66)
REP (Shiba et al. 2000) 51 years 
(8–87 years)
196 Medical record review 1.9 (1.1–3.2) Within 5 years
Anxiety EPIC-Norfolk (Ishihara-
Paul et al. 2008)
41–80 Median, 8 years 175 Structured 
questionnaire
2.7 (1.5–4.7)
HPFS, men only 
(Weisskopf et al. 2003)
56.0 (42–77) ≤ 12 years 189 Crown–Crisp anxiety 
index
Score ≥ 4 vs. 0–1: 1.5 
(1.0–2.1)
Could be > 2 years
REP (Bower et al. 2010) 48.3 (20–69) Mean, 29 years 
(up to 45 years)
156 MMPI Quartile 4 vs. quartiles 1–3: 
1.63 (1.16–2.27)/ 
men 2.03 (1.28–3.24)/ 
women 1.29 (0.79–2.10)
REP (Shiba et al. 2000) 51 years (8–87) 196 Medical record review 2.2 (1.4–3.4); slightly 
attenuated, even restricted 
to > 20 years before index 
date
Could be > 20 years
Abbreviations: BSIT, brief smell identification test; EPIC, European Prospective Investigation into Cancer; HAAS, Honolulu Asia Aging Study; HPFS, Health Professionals Follow-up 
Study; HR, Hazard Ratio; MMPI, Minnesota Multiphasic Personality Inventory; NHS, Nurse’s Health Study; NIH-AARP DH, National Institutes of Health-AARP Diet and Health study; 
OR, odds ratio; RBD, rapid eye movement sleep behavior disorder; REP, Rochester Epidemiology Project; RR, relative risk.
aThe time from measurement of non-motor symptoms to PD diagnosis are best estimates; these estimates could, however, be misleading because they were bounded by the length of 
follow-up and inclusion criteria. bThe HAAS and HPFS/NHS used the frequency of bowel movement as an indicator for constipation. cThe NIH-AARP DH used daytime napping duration 
as a surrogate for daytime sleepiness. dBased on follow-ups of RBD patients.Parkinson’s pre-motor research
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develops in the PD brain in six sequential 
stages. α-Synuclein pathology begins in the 
dorsal motor nucleus of the vagus and glosso-
pharyngeal nerves and the anterior olfactory 
nucleus in stage 1, extends to the locus ceruleus 
and caudal raphe nuclei in the pons (stage 2), 
then to the substantia nigra (stage 3), to the 
temporal mesocortex (stage 4), and finally to 
the neocortex (stages 5–6). A later extension of 
this hypothe  sis further posits that the synucle-
inopathy may even first develop in the enteric 
nerves in the gut and later spread along the 
vagus nerve into the brain (Hawkes et al. 2007, 
2009). Importantly, according to the Braak 
hypothesis, the irreversible loss of dopamine 
neurons in the substantia nigra and associated 
progressive motor dysfunction may not be evi-
dent until Braak stages 3 and 4. Although the 
Braak hypothesis is not universally supported 
(Burke et al. 2008; Dickson et al. 2010), it 
presents the intriguing possibility that the 
extra-nigra, nondopaminergic pathologies are 
intrinsic to early PD pathogenesis and that 
premotor symptoms could well be part of the 
  disease’s natural history (Hawkes et al. 2010).
Growing evidence on the importance of 
premotor symptoms, coupled with the Braak 
hypothesis, has generated substantial inter-
est in understanding the origins and conse-
quences of these symptoms. Clinical research 
primarily has focused on evaluating premotor 
symptoms and other factors as markers for the 
future development of PD, a subject elegantly 
reviewed by Berg et al. (2012). Another poten-
tial line of inquiry is based on the idea that 
the presence of multiple premotor symptoms 
in the same individual represents common 
underlying pathogeneses that may eventually 
lead to PD, and thus premotor symptoms 
may provide a unique opportunity to under-
stand the etiology of PD (Hawkes et al. 2007, 
2009). Despite this potential promise, little 
research has been carried out to understand 
the etiological implications of the premotor 
symptoms of PD.
This review was based on a workshop, 
Parkinson’s Disease Premotor Symptom 
Symposium, held 7–8 June 2012 at the 
National Institute of Environmental 
Health Sciences in Research Triangle Park, 
North Carolina.
A comprehensive review of the clinical 
and epidemiological evidence for the exis-
tence of these premotor symptoms in PD is 
outside the scope of this review. Instead, we 
focus on outlining the promises and pitfalls 
of the concept of premotor symptoms and on 
developing research priorities and strategies 
for understanding the clinical and etiological 
implications of these symptoms. Although 
these symptoms can also develop after the 
clinical diagnosis of PD, for this review, we 
focus on the period prior to the emergence of 
diagnostic motor abnormalities.
Identification of High-Risk 
Popu lations
Several important studies have tested the 
hypothesis that premotor symptoms, 
coupled with neuro  imaging, may lead to 
early identifi  ca  tion, or even diagnosis, of PD 
(Lang 2011; Tolosa et al. 2009). Preliminary 
results have been published from the 
Prospective Evaluation of Risk Factors for 
Idiopathic Parkinson’s Syndrome (PRIPS) 
study (Berg et al. 2013) and the Parkinson 
At-Risk Syndrome (PARS) study (Siderowf 
et al. 2012). PRIPS aimed to test a two-stage 
screening strategy for early identification of 
PD cases utilizing the following predictors: 
hyposmia, PD family history, subtle motor 
impairment, and substantia nigra hyper-
echogenicity (SN+). This general population– 
based cohort recruited 1,352 participants 
≥ 50 years of age (mean age, 59 years). 
Hyposmia was evaluated using the Sniffin’ 
Stick test (Hummel et al. 2001) and SN+ by 
trans  cranial sonography. A total of 10 partici-
pants developed PD during approximately 
3 years of follow-up. Hyposmia was strongly 
associated with the risk of developing PD with 
sensitivity and specificity both > 70%. The 
positive predictive value (PPV), however, was 
only 2%, in part due to the low PD incidence 
in this relatively young population. Combining 
hyposmia with other characteristics (e.g., 
family history or SN+) only slightly increased 
the PPV, but substantially decreased the 
sensitivity. Unlike the PRIPS study, PARS was 
conducted among a risk-enriched population 
in which 45% of the 4,999 study participants 
(mean age, 64 years) had a family history of 
PD. The study was designed to evaluate a two-
stage strategy of at-risk identification: olfactory 
testing using the University of Pennsylvania 
Smell Identification Test (Doty et al. 1984), 
followed by dopamine-transporter (DAT) 
imaging. Although findings on the DAT scan 
portion are yet to be published, preliminary 
analyses showed that participants with 
hyposmia were more likely to have other non-
motor features and to report changes in motor 
function (Siderowf et al. 2012).
Of the premotor symptoms, the PRIPS and 
PARS studies focused on hyposmia. The results 
from these studies, albeit preliminary, clearly 
show that an individual premotor symptom by 
itself is inadequate for early disease identifica-
tion. This is actually what one would expect 
for a relatively rare disease such as PD because 
the PPV depends on the prevalence of pre-
diagnostic cases in the target population.
The utility of combinations of premotor 
symptoms for early disease identification has 
been little explored and merits consideration. 
Although the underlying etiologies of pre-
motor symptoms in the general population 
are likely diverse, the presence of multiple 
symptoms in individuals who later develop 
PD may reflect common or similar under-
lying pathologies, for example Lewy pathol-
ogy in various sites of the brain, spinal cord, 
and autonomic nervous system. In support 
of this notion, in the HAAS, both the sense 
of smell (Ross et al. 2006) and bowel move-
ment frequency (Abbott et al. 2007) were 
strongly related to incidental Lewy body dis-
ease among individuals without PD. Further, 
α-synuclein was identified from colon tissues 
of PD patients collected 2–5 years before PD 
motor onset (Shannon et al. 2012), but not in 
any of the controls.
One may further hypothesize that among 
individuals who will develop PD, multiple 
premotor symptoms develop over time as a 
result of common pathologies and eventually 
become a clinically recognizable syndrome 
several years before PD diagnosis (Figure 1). 
In contrast, among individuals who will 
not develop PD, these symptoms may also 
exist, but they are more independent of each 
other and more randomly distributed over 
the entire life period. Therefore, the joint 
prevalence of multiple premotor symptoms 
in a low-risk population will be low. These 
hypotheses are yet to be systematically exam-
ined, but there are preliminary supportive 
data. Based on hyposmia, infrequent bowel 
movement, slow reaction time, and excessive 
daytime sleepiness, the HAAS showed that 
2 of the 24 individuals with more than three 
of these symptoms developed PD within 
4.6 years of follow-up, as compared with 8 of 
852 for those with only one symptom (Berg 
et al. 2012). Preliminary evidence also comes 
from research in high-risk populations. Non-
Parkinsonian family members of patients 
with the leucine-rich repeat kinase 2 (LRRK2 
G2019S) mutation showed more constipa-
tion and poorer color discrimination than 
controls (Marras et al. 2011). Therefore, pre-
liminary evidence does suggest that multi  ple 
non-motor symptoms tend to cooccur among 
individuals at higher risk for PD.
It is also important to understand when 
multiple premotor symptoms become detect-
able in the prodromal stage of PD. Ideally, 
this should be investigated in large prospec-
tive cohorts with long follow-up and repeated 
measurements of multiple premotor symp-
toms. In reality, we have just begun to under-
stand the temporal relationships between 
individual symptoms and PD by examining 
existing clinical data or data from prospec-
tive cohorts (Table 1). For example, several 
clinical studies have consistently documented 
RBD onset about 10–20 years before PD 
onset (Boeve and Saper 2006; Claassen et al. 
2010; Iranzo et al. 2006; Postuma et al. 
2009; Schenck et al. 1996). These were stud-
ies of RBD patients who were diagnosed by 
polysomnography, and it has yet to be deter-
mined whether this clinical observation can Chen et al.
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be generalized to the general elderly popula-
tion where only questionnaire-based screen-
ing for probable RBD is possible (Postuma 
et al. 2012a). Data on the timing of other 
key premotor symptoms are limited or incon-
sistent. For example, several studies showed 
that constipation might precede PD clinical 
diagnosis by 10–20 years in men (Abbott 
et al. 2001; Gao X et al. 2011; Savica et al. 
2009), but data are not consistent in women 
(Gao X et al. 2011; Savica et al. 2009). The 
population-based HAAS showed that hypos-
mia was highly predictive of PD onset within 
4 years after symptom assessment (Ross et al. 
2008). Two other studies among high-risk 
individuals (Ponsen et al. 2009; Postuma et al. 
2011) showed that hyposmia predicted PD 
risk throughout the entire follow-up period 
of 5 years. Because the assessment of temporal 
relationship will be bounded by the length 
of follow-up, future studies should have lon-
ger periods of follow-up and repeated symp-
tom assessments. More importantly, future 
studies should also investigate the temporal 
pattern of multiple premotor symptoms in 
  prodromal PD cases.
Measuring premotor symptoms for 
neuro  degeneration research represents a sub-
stantial challenge. Studies to date have mostly 
used simple methods to identify premotor 
symptoms, including methods such as self-
reported symptoms, self-reported diagnoses, 
screening tests, and structured questionnaires. 
For example, the sense of smell is often mea-
sured with simple screening tests such as the 
Brief Smell Identification Test (Ross et al. 
2008) or the Sniffin’ Stick Test (Hummel 
et al. 2001), and hyposmia is defined as a 
score below population norms. These simple 
methods have served well to establish the 
associations between premotor symptoms 
and PD. However, because most premotor 
symptoms are common in the elderly and 
are etiologically heterogeneous (Doty 2009; 
Leung et al. 2011), novel approaches are 
needed to assess various modalities of these 
symptoms and to identify patterns that are 
more specific to PD. Compared to other 
premotor symptoms, RBD is more specific; 
however, its diagnosis requires polysomno-
graphic confirmation at sleep clinics. Several 
screening questionnaires for probable RBD 
(Boeve et al. 2011; Li et al. 2009; Postuma 
et al. 2012a; Stiasny-Kolster et al. 2007) have 
been developed and validated in clinical set-
tings, but their validities in identifying RBD 
patients from the general population are yet 
to be evaluated.
A large prospective study reported subjec-
tive complaints of motor dysfunctions such 
as stiffness and tremor prior to PD diagnosis 
(de Lau et al. 2006). In fact, subtle motor 
abnormalities have been quantitatively docu-
mented among individuals at high risk for 
PD. For example, Mirelman et al. (2011) 
reported subtle gait changes among asymp-
tomatic carriers of LRRK2 mutation with 
quantified gait analyses under challenged 
conditions. Among RBD patients, Postuma 
et al. (2012b) docu  mented multiple motor 
abnormalities on average 6–8 years prior 
to PD diagnosis, including voice and face 
akinesia, rigidity, abnormal gait, limb brady-
kinesia. Evaluation of subtle motor changes 
in addition to premotor symptoms may prove 
important in differentiating PD from other 
causes of non-motor symptoms. Further, the 
development and use of standardized assess-
ment tools for non-motor and motor symp-
toms such as the National Institues of Health/
National Institute of Neurological Disorders 
and Stroke (NIH/NINDS) common data 
elements for PD will greatly facilitate such 
research (NINDS 2013).
Implications for Parkinson’s 
Etiology and Experimental 
Research 
An inherent implication of research on pre-
motor symptoms is that it may eventually 
lead to a better understanding of PD etiology 
(Hawkes et al. 2007, 2009). The concept that 
premotor symptoms represent intermediate 
phenotypes prior to overt PD may offer us 
a vehicle to understand the roles of genetics 
and environment in the early stages of PD 
development. For example, neurotoxicants 
or viruses may enter the body via the nasal 
cavity or the digestive tract (Hawkes et al. 
2007, 2009), and, in susceptible individu-
als, may initiate Lewy pathology in the olfac-
tory bulb or the enteric nerves (Doty 2008; 
Hawkes et al. 2007, 2009; Reichmann 2011); 
over time, this may lead to premotor symp-
toms such as hyposmia or constipation and 
may eventually progress to PD. It is there-
fore important to identify environmental and 
genetic factors associated with the presence 
of multiple premotor symptoms and, more 
importantly, to identify factors that may pre-
vent the progression of premotor symptoms 
to clinical PD. This concept is illustrated 
in Figure 2.
To the best of our knowledge, no epide-
miological study has examined common etio-
logical factors for the presence of multiple 
non-motor symptoms. Preliminary data are 
available only on risk factors for individual 
symptoms. Postuma et al. (2012c) recently 
published the first report on environmen-
tal risk factors for RBD. In this multicenter 
study of 347 cases and 347 controls, RBD was 
positively associated with pesticide exposure 
and head injury. However, unlike PD, RBD 
was more common among smokers and was 
not related to caffeine intake. More studies 
have examined risk factors associated with 
hyposmia. All studies found that the risk of 
hyposmia increases with age and is higher in 
men than in women (Brämerson et al. 2004; 
Schubert et al. 2011, 2012; Siderowf et al. 
2007, 2012; Vennemann et al. 2008). Data 
on smoking or coffee drinking and hyposmia 
are, however, preliminary and inconsistent 
(Brämerson et al. 2004; Schubert et al. 2011, 
2012; Siderowf et al. 2007, 2012; Vennemann 
Figure 1. A hypothesis on the development of premotor symptoms among persons who will or will not 
develop PD in lifetime. The green lines represent the joint prevalence of multiple premotor symptoms by 
age; solid, future PD cases, and dashed for noncases. The red line represents motor signs among future 
PD patients. The blue line represents the loss of dopaminergic neurons in the substantia nigra pars com-
pacta of PD patients which underlies cardinal motor signs. PD diagnosis is made based on cardinal motor 
signs (red) when approximately 50% of the dopaminergic neurons in the substantia nigra have been lost 
(threshold shown as the black dotted line). Individuals at high risk for PD (solid green line) will develop 
multiple premotor symptoms years before onset of PD motor signs; for individuals who will not develop PD 
(dashed green line), the joint prevalence of these symptoms remain at low level even at older age.
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et al. 2008), although current smoking is asso-
ciated with a higher risk of hyposmia in some 
studies (Schubert et al. 2012; Vennemann 
et al. 2008). In adults, the prevalence of con-
stipation is higher in women and increases 
modestly with age (McCrea et al. 2009; Suares 
and Ford 2011). Other suspected risk fac-
tors for constipation include inadequate fluid 
or dietary fiber intake, less physical activity, 
concurrent use of certain medications, levels 
of thyroid hormone and progesterone, and 
a wide range of medical conditions includ-
ing neurodegenerative diseases (Leung 2007; 
Leung et al. 2011). Therefore, risk factors for 
individual non-motor symptoms are diverse, 
and PD-related pathology is probably only a 
small contributor to the prevalence of each 
of these symptoms. Combining multiple pre-
motor symptoms may rule out some diverse 
pathologies unrelated to PD. Further, PD is 
likely to be phenotypically and etiologically 
hetero  geneous (van Rooden et al. 2009, 2011); 
and careful phenotyping of various PD motor 
and non-motor symptoms may help us under-
stand the interrelationship among risk factors, 
premotor symptoms, and neurodegeneration.
Although human observational studies are 
essential to define premotor symptoms and 
their relationship to PD development, experi-
mental studies are needed to understand the 
underlying biology and to examine novel 
etiological hypotheses. For example, could 
the gastrointestinal tract or the olfactory bulb 
be the sites of initial exposure to a pathogenic 
environmental agent (Reichmann 2011)? 
Does pathology progress anatomically, as 
the Braak hypothesis predicts (Pan-Montojo 
et al. 2012)? Does the selectivity and order 
of neuro  degeneration in PD reflect differ-
ential sensitivity to environmental agents or 
some other mechanism of progression such as 
prion-like spreading (Dunning et al. 2012)? 
Experimental research that models prodromal 
PD may help answer these questions.
Animal models based on toxicants [e.g., 
1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), 6-hydroxydopamine (6-OHDA), 
paraquat, rotenone] and those based on genes 
[e.g., SNCA (α-synuclein), LRRK2, PINK1 
(PTEN-induced putative kinase 1), PARK2 
(parkin)] have been used for PD research 
(Bezard et al. 2012; Blesa et al. 2012). These 
models were developed to mimic features of 
late-stage PD such as dopaminergic neuron 
loss and motor dysfunction, or to recapitulate 
particular pathogenic processes such as neuro-
inflammation. The extent to which current 
models replicate the non-motor features of PD 
is incompletely known at present, although 
recent work has revealed some intriguing 
results suggesting abnormalities analogous to 
non-motor features of PD (Jellinger 2011; 
McDowell and Chesselet 2012; Smith 
et al. 2012).
Central to this work is the availability 
of validated methods to evaluate olfaction, 
gastro  intestinal function, sleep disturbances, 
or depression/anxiety in experimental ani-
mals. The technical difficulties of reliably 
determining the presence or absence of these 
non-motor features in experimental animals 
are not trivial. Furthermore, the mechanistic 
relationship between abnormalities observed 
in the commonly used assays in experimen-
tal animals and the analogous symptoms in 
human patients is uncertain, especially for 
complex behavioral traits such as depression 
and anxiety. Nonetheless, ways to evalu-
ate these non-motor symptoms have been 
reported in mice, rats, primates, and zebra-
fish. Each of these animals shows phylo-
genetic conservation of neuro  anatomical 
structures involved in early Braak stages of 
PD pathology, suggesting that they might be 
employed as models to study premotor PD.
So far, a number of animal models of 
PD have shown either non-motor functional 
abnormalities or pathology outside the sub-
stantia nigra. Olfactory function has been 
shown to be abnormal in MPTP-treated 
rodents (Schintu et al. 2009), transgenic 
mice expressing α-synuclein under a neuro-
nal regulatory element derived from the Thy1 
gene (Thy1-αSyn) (Fleming et al. 2008), and 
mice expressing reduced levels of the vesicular 
monoamine transporter (VMAT) (Taylor et al. 
2009). Sleep and circadian rhythm are known 
to be disrupted in MPTP-treated rodents 
(Laloux et al. 2008), rotenone-treated rats 
(García-García et al. 2005), and Thy1-αSyn 
mice and VMAT2-deficient mice (Taylor 
et al. 2009). Gastrointestinal function has been 
shown to be abnormal in MPTP-treated mice 
(Anderson et al. 2007), rotenone-treated rats 
(Drolet et al. 2009), Thy1-αSyn mice (Wang 
et al. 2008, 2012), SNCA PAC mice (which 
expresss mutant human α-synuclein from a 
P1 artificial chromo  some containing its endog-
enous regulatory elements) (Kuo et al. 2010), 
and VMAT2-deficient mice (Taylor et al. 
2009). These findings are of interest because 
they demonstrate that toxicant exposures and 
genetic manipulations used to induce motor 
signs of PD can also induce non-motor fea-
tures. This suggests that at least some of the 
neuronal populations underlying non-motor 
symptoms share susceptibility with dopamine 
neurons to agents implicated in motor PD 
pathogenesis. This is consistent with a model 
in which common etiological mechanisms 
could underlie both motor and non-motor 
components of the disease.
Interestingly, a few of the models have 
shown ordered progression from non-motor 
to motor symptoms. Thy1-αSyn transgenic 
mice showed α-synuclein inclusions in 
the olfactory bulb and deficits in olfactory 
function on multiple tests by 3 months of 
age (Fleming et al. 2008). By this time point, 
animals also showed progressively worsening 
sleep abnormalities (Kudo et al. 2011) and 
progressive reduction in stool frequency (Wang 
et al. 2012). These changes preceded loss of 
striatal dopamine, which did not occur until 
14 months of age (Lam et al. 2011). Similarly, 
VMAT2-deficient mice demonstrated pro-
gres  sive non-motor symptoms prior to 
the onset of motor deficits (Taylor et al. 
2009). Gastrointestinal dysfunction was 
seen at 2 months of age, olfactory defects 
by 5 months, and anxiety-like behavior 
at 6 months. l-dihydroxyphenylalanine 
(l-DOPA)–  responsive hypo  kinesia and loss 
of striatal tyrosine hydroxylase terminals were 
present by 18 months of age, and loss of 
nigral dopamine neurons worsened between 
18 and 24 months (Caudle et al. 2007). 
Data from both models imply that a systemic 
abnormality affecting all cells can result in 
specific abnormalities of neuronal populations 
implicated in non-motor and motor PD with 
replication of some of the temporal course.
These data do not yet allow us to dis-
tinguish between a model for pathogenic 
Figure 2. A hypothesis on risk factors, premotor symptoms, and PD. Environmental or genetic factors may 
initiate neurodegeneration through mechanisms such as neuroinflammation; in susceptible individuals, 
this may first lead to premotor symptoms years before PD clinical onset; if this neurodegeneration contin-
ues without effective intervention, premotor symptoms may eventually progress into overt PD; however, 
with interventions such as coffee drinking, this premotor progression may be halted before it becomes 
irreversible.
Clinical PD
Environment
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head injury)
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progression in which the temporal course 
of the disease is dictated by the differential 
vulnerability of various neuronal groups to 
a systemic abnormality and an alternative 
model in which pathology spreads anatomi-
cally from one site of the nervous system to 
another to produce progressive symptoms. 
Much recent attention has been given to the 
idea that α-synuclein has prion-like properties 
and that α-synucleinopathy can spread from 
a site of initial pathology to other regions of 
the central nervous system (CNS) by axonal 
transport and cell-to-cell spread (Luk et al. 
2012). In this regard, it is noteworthy that the 
pathology in both Thy1-αSyn mice (Fleming 
et al. 2004) and VMAT2-deficient mice 
(Taylor et al. 2009) is dependent on the pres-
ence of α-synuclein. However, several alterna-
tive explanations for the progression of disease 
are equally consistent with the available data 
and further studies will be necessary to deter-
mine whether progression can be arrested by 
interventions that prevent the transport or 
transmission of pathological α-synuclein spe-
cies, or whether additional cellular factors dic-
tate the differential vulnerability of neuronal 
groups involved in non-motor symptoms.
The hypothesis that an environmental 
agent could provoke pathology at an anatomi-
cal site of entry that then progresses to involve 
other structures, culminating in degeneration 
of the substantia nigra, has received some pre-
liminary experimental support. For example, 
Jang et al. (2009) reported that, in mice, intra-
nasally injected H5N1 influenza virus trav-
elled from the enteric nervous system (ENS) 
into the CNS and eventually caused degenera-
tion of dopaminergic neurons. Further, this 
sequence was accompanied by chronic neuro-
inflammation with microglial activation and 
elevated expression of cytokines and other pro-
inflammatory biomarkers (Jang et al. 2012). 
These findings imply that initiating patho-
genic events can provoke distinct secondary 
mechanisms underlying disease progression, 
with the important implication that environ-
mental agents that trigger early events in PD 
pathogenesis may no longer be present at the 
end stage of the disease, when tissue samples 
are generally available for analysis.
The gastrointestinal tract is potentially 
an important site for exposure to envi-
ronmental agents, and the suggestion that 
α-synuclein pathology in the ENS may be 
one of the first abnormalities in PD patients 
has promoted interest in the possibility of 
modeling pathology in the ENS and its sub-
sequent progression to the CNS. Transgenic 
mice expressing human α-synuclein under its 
own regulatory elements showed prominent 
ENS pathology, but no progression to other 
features of PD (Kuo et al. 2010), suggesting 
that a second event was necessary to promote 
disease progression. Recent reports showed 
that intra  gastric rotenone caused α-synuclein 
aggregation in mice, following a staged 
pattern that was consistent with the Braak 
hypothesis (Pan-Montojo and Funk 2010; 
Pan-Montojo et al. 2010), and resection of 
the autonomic nerves prevented this progres-
sion (Pan-Montojo et al. 2012). These inter-
esting observations are yet to be replicated by 
other laboratories, and their interpretation 
consequently remains speculative. However, 
the local microenvironment of the gastro-
intestinal tract remains a potentially signifi-
cant factor in dictating initiating pathogenic 
events, and is worthy of further investigation. 
This might also encompass evaluation of the 
role of the gut microbiome, which could be 
experimentally manipulated in animal models 
to determine whether alterations can initiate 
PD pathology or modulate the time course of 
onset of pathology and progression. Although 
few empirical data exist regarding the role of 
the microbiome in PD, the microbiome influ-
ences the immune system, gastrointestinal 
mobility, and the metabolism of nutrients 
and other exogenous chemicals (Grenham 
et al. 2011), all of which may potentially con-
tribute to the development of PD. Similarly, 
experimental animals could be exposed to 
toxicants through the gastrointestinal tract 
to evaluate whether etiologically implicated 
exogenous agents can provoke the earliest 
pathological changes of PD or modulate their 
appearance in experimental models. These 
studies could provide valuable mechanistic 
insights and generate further hypotheses to be 
addressed in human studies.
Finally, although this review focuses on 
PD, research on premotor symptoms may 
have broader implications because many of 
these symptoms have been linked to other 
neurological diseases. For example, hypos-
mia is associated with higher risk of cogni-
tive decline and Alzheimer’s disease (Wilson 
et al. 2007, 2009), and RBD precedes Lewy 
body dementia and multiple system atro-
phy (Schenck et al. 2013). Further, olfac-
tory dysfunction has been documented in 
schizophrenic patients and individuals at high 
risk for schizophrenia (Moberg et al. 2013). 
Therefore research on premotor symptoms 
may eventually provide novel insights into 
the natural history and etiology of neuro-
degeneration and related conditions in 
addition to PD, and into the complex inter-
relationships among these conditions.
Conclusion
Premotor symptoms of PD may offer us an 
excellent opportunity to identify populations 
at higher risk for PD and to understand early 
disease etiology. Further research is needed 
to understand whether the presence of mul-
tiple premotor symptoms is predictive of PD. 
Animal experiments may help to understand 
the biology of these non-motor symptoms 
and test novel etiological hypothesis. At the 
current time, our understanding of these pre-
motor symptoms is still in its infancy and the 
research calls for close multidisciplinary col-
laborations among clinicians, epidemiologists, 
basic scientists, and geneticists.
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